tiprankstipranks
Trending News
More News >
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
US Market

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

Compare
1,185 Followers
See the Price Targets and Ratings of:

BBIO Analyst Ratings

Strong Buy
15Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
Based on 15 analysts giving stock ratings to
BridgeBio
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$60.14
▲(81.69%Upside)
Based on 15 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $60.14 with a high forecast of $95.00 and a low forecast of $37.00. The average price target represents a 81.69% change from the last price of $33.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","96":"$96","41.25":"$41.3","59.5":"$59.5","77.75":"$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41.25,59.5,77.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.4,42.753846153846155,47.107692307692304,51.46153846153846,55.815384615384616,60.16923076923077,64.52307692307693,68.87692307692308,73.23076923076923,77.58461538461539,81.93846153846155,86.2923076923077,90.64615384615385,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.4,40.07230769230769,41.744615384615386,43.41692307692308,45.08923076923077,46.761538461538464,48.433846153846154,50.106153846153845,51.77846153846154,53.45076923076923,55.12307692307692,56.79538461538462,58.46769230769231,{"y":60.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.4,38.29230769230769,38.184615384615384,38.07692307692307,37.96923076923077,37.86153846153846,37.753846153846155,37.646153846153844,37.53846153846154,37.43076923076923,37.323076923076925,37.215384615384615,37.10769230769231,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.03,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$95.00Average Price Target$60.14Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BBIO
TipRanks AITipRanks
Not Ranked
TipRanks
$33
Hold
-0.30%
Downside
Reiterated
05/14/25
BridgeBio Pharma's stock is rated at 47, reflecting strong revenue growth but significant financial challenges. The positive earnings call and strategic financial moves are encouraging, yet high leverage and negative equity remain concerns. Technical indicators show potential downward pressure, while valuation measures suggest the stock may be overvalued given its unprofitability.
J.P. Morgan Analyst forecast on BBIO
Anupam RamaJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/25
BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating
Bank of America Securities Analyst forecast on BBIO
Jason ZemanskyBank of America Securities
Bank of America Securities
$50
Buy
51.06%
Upside
Reiterated
05/16/25
BridgeBio Pharma: Promising Outlook with Strong Execution and Growth Potential
TD Cowen
$60
Buy
81.27%
Upside
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS) and BridgeBio Pharma (NASDAQ: BBIO)
Mizuho Securities Analyst forecast on BBIO
Salim SyedMizuho Securities
Mizuho Securities
$53$60
Buy
81.27%
Upside
Reiterated
05/02/25
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
Evercore ISI Analyst forecast on BBIO
Cory KasimovEvercore ISI
Evercore ISI
$60$70
Buy
111.48%
Upside
Reiterated
04/30/25
Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)
Piper Sandler Analyst forecast on BBIO
Biren AminPiper Sandler
Piper Sandler
$46$63
Buy
90.33%
Upside
Reiterated
04/30/25
Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
Scotiabank Analyst forecast on BBIO
Greg HarrisonScotiabank
Scotiabank
$52$55
Buy
66.16%
Upside
Reiterated
04/30/25
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and BridgeBio Pharma (NASDAQ: BBIO)
UBS
$65$72
Buy
117.52%
Upside
Reiterated
04/30/25
BridgeBio price target raised to $72 from $65 at UBSBridgeBio price target raised to $72 from $65 at UBS
Cantor Fitzgerald Analyst forecast on BBIO
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$95
Buy
187.01%
Upside
Reiterated
04/29/25
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
Wells Fargo Analyst forecast on BBIO
Tiago FauthWells Fargo
Wells Fargo
$67
Buy
102.42%
Upside
Reiterated
04/29/25
Wells Fargo Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
Leerink Partners Analyst forecast on BBIO
Mani ForooharLeerink Partners
Leerink Partners
$48$53
Buy
60.12%
Upside
Reiterated
04/29/25
BridgeBio Pharma's Strong Financial Performance and Promising Pipeline Justify Buy Rating
BMO Capital Analyst forecast on BBIO
Kostas BiliourisBMO Capital
BMO Capital
$37
Hold
11.78%
Upside
Reiterated
04/29/25
Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
H.C. Wainwright Analyst forecast on BBIO
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$49$53
Buy
60.12%
Upside
Reiterated
04/15/25
BridgeBio price target raised to $53 from $49 at H.C. WainwrightBridgeBio price target raised to $53 from $49 at H.C. Wainwright
Raymond James Analyst forecast on BBIO
Danielle BrillRaymond James
Raymond James
$57
Buy
72.21%
Upside
Reiterated
04/01/25
Raymond James reiterates Outperform Rating on BridgeBio Pharma (BBIO)Raymond James analyst Danielle Brill reiterated an Outperform rating and $57.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BBIO
TipRanks AITipRanks
Not Ranked
TipRanks
$33
Hold
-0.30%
Downside
Reiterated
05/14/25
BridgeBio Pharma's stock is rated at 47, reflecting strong revenue growth but significant financial challenges. The positive earnings call and strategic financial moves are encouraging, yet high leverage and negative equity remain concerns. Technical indicators show potential downward pressure, while valuation measures suggest the stock may be overvalued given its unprofitability.
J.P. Morgan Analyst forecast on BBIO
Anupam RamaJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/25
BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating
Bank of America Securities Analyst forecast on BBIO
Jason ZemanskyBank of America Securities
Bank of America Securities
$50
Buy
51.06%
Upside
Reiterated
05/16/25
BridgeBio Pharma: Promising Outlook with Strong Execution and Growth Potential
TD Cowen
$60
Buy
81.27%
Upside
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS) and BridgeBio Pharma (NASDAQ: BBIO)
Mizuho Securities Analyst forecast on BBIO
Salim SyedMizuho Securities
Mizuho Securities
$53$60
Buy
81.27%
Upside
Reiterated
05/02/25
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
Evercore ISI Analyst forecast on BBIO
Cory KasimovEvercore ISI
Evercore ISI
$60$70
Buy
111.48%
Upside
Reiterated
04/30/25
Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)
Piper Sandler Analyst forecast on BBIO
Biren AminPiper Sandler
Piper Sandler
$46$63
Buy
90.33%
Upside
Reiterated
04/30/25
Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
Scotiabank Analyst forecast on BBIO
Greg HarrisonScotiabank
Scotiabank
$52$55
Buy
66.16%
Upside
Reiterated
04/30/25
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and BridgeBio Pharma (NASDAQ: BBIO)
UBS
$65$72
Buy
117.52%
Upside
Reiterated
04/30/25
BridgeBio price target raised to $72 from $65 at UBSBridgeBio price target raised to $72 from $65 at UBS
Cantor Fitzgerald Analyst forecast on BBIO
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$95
Buy
187.01%
Upside
Reiterated
04/29/25
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
Wells Fargo Analyst forecast on BBIO
Tiago FauthWells Fargo
Wells Fargo
$67
Buy
102.42%
Upside
Reiterated
04/29/25
Wells Fargo Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
Leerink Partners Analyst forecast on BBIO
Mani ForooharLeerink Partners
Leerink Partners
$48$53
Buy
60.12%
Upside
Reiterated
04/29/25
BridgeBio Pharma's Strong Financial Performance and Promising Pipeline Justify Buy Rating
BMO Capital Analyst forecast on BBIO
Kostas BiliourisBMO Capital
BMO Capital
$37
Hold
11.78%
Upside
Reiterated
04/29/25
Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
H.C. Wainwright Analyst forecast on BBIO
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$49$53
Buy
60.12%
Upside
Reiterated
04/15/25
BridgeBio price target raised to $53 from $49 at H.C. WainwrightBridgeBio price target raised to $53 from $49 at H.C. Wainwright
Raymond James Analyst forecast on BBIO
Danielle BrillRaymond James
Raymond James
$57
Buy
72.21%
Upside
Reiterated
04/01/25
Raymond James reiterates Outperform Rating on BridgeBio Pharma (BBIO)Raymond James analyst Danielle Brill reiterated an Outperform rating and $57.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

1 Month
xxx
Success Rate
11/21 ratings generated profit
52%
Average Return
+10.95%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.38% of your transactions generating a profit, with an average return of +10.95% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
57%
Average Return
+9.71%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +9.71% per trade.
1 Year
Success Rate
13/19 ratings generated profit
68%
Average Return
+23.07%
reiterated a buy rating 24 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +23.07% per trade.
2 Years
xxx
Success Rate
18/21 ratings generated profit
86%
Average Return
+63.18%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +63.18% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
20
10
10
16
14
Buy
14
20
27
26
17
Hold
5
2
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
32
39
43
32
In the current month, BBIO has received 31 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 60.14.
Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.79 with a range of -$1.10 to -$0.34. The previous quarter’s EPS was -$0.88. BBIO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.86% of the time in the same period. In the last calendar year BBIO has Outperformed its overall industry.
Next quarter’s earnings estimate for BBIO is -$0.79 with a range of -$1.10 to -$0.34. The previous quarter’s EPS was -$0.88. BBIO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.86% of the time in the same period. In the last calendar year BBIO has Outperformed its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $91.25M with a range of $40.00M to $198.50M. The previous quarter’s sales results were $116.63M. BBIO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 49.12% of the time in the same period. In the last calendar year BBIO has Outperformed its overall industry.
Next quarter’s sales forecast for BBIO is $91.25M with a range of $40.00M to $198.50M. The previous quarter’s sales results were $116.63M. BBIO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 49.12% of the time in the same period. In the last calendar year BBIO has Outperformed its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 60.14.
    What is BBIO’s upside potential, based on the analysts’ average price target?
    BridgeBio Pharma Inc has 81.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BBIO a Buy, Sell or Hold?
          BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
            What is BridgeBio Pharma Inc’s price target?
            The average price target for BridgeBio Pharma Inc is 60.14. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $95.00 ,the lowest forecast is $37.00. The average price target represents 81.69% Increase from the current price of $33.1.
              What do analysts say about BridgeBio Pharma Inc?
              BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of BBIO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis